Rising global prevalence of chronic diseases like non-alcoholic steatohepatitis (NASH) and neurodegenerative disorders is driving urgent demand for advanced diagnostic tools. MRE offers a non-invasive method to assess tissue elasticity, crucial for early detection and monitoring. This technology's ability to standardize MRE analysis and improve data quality aligns perfectly with the shift towards objective, data-driven diagnostics and precision medicine, making it a critical asset for healthcare innovation worldwide.
Significantly Improves Diagnostic Accuracy and Reproducibility: Utilizes automated region setting, independent of user subjectivity, to dramatically enhance MRE image reliability and increase elasticity measurement precision and reproducibility.
Optimizes Examination Efficiency and Data Quality: Automatically adjusts the discrimination region size based on propagation wavelength, supporting optimal data acquisition during examinations and streamlining the diagnostic process.
Establishes Market Advantage Through High Uniqueness: The technology's distinctiveness is highlighted by only two prior art documents cited by the examiner, suggesting strong potential for early market share capture.
This patent specifically protects the configuration of an imaging apparatus centered on 'region size adjustment means' and 'discrimination means' for MRE image analysis. Its strong originality was recognized with only two prior art documents cited by the examiner, leading to a swift patent grant and indicating a stable and robust scope of protection.
While this patent secures core MRE image analysis algorithms, white space exists in developing novel MRE hardware components, integrating MRE with other multi-modal imaging techniques, or exploring new applications in non-medical fields like material science or industrial inspection.
Assuming a medium-sized hospital conducts 5,000 MRE examinations annually, with a cost of $200/examination (AI est.). Implementing this technology could reduce the re-examination rate by 7% (from 10% to 3%), eliminating 350 re-examinations annually (5,000 cases × 7% = 350 cases). This results in direct cost savings of $70K/year (AI est.) (350 cases × $200). Including indirect benefits such as improved patient throughput from faster, more accurate diagnoses, reduced medical litigation risk from fewer misdiagnoses, and enhanced treatment efficacy through early detection, the total economic impact is estimated at ~$1.0M/year (AI est.).
X: Diagnostic Reproducibility
Y: Examination Efficiency